These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 35967405)

  • 1. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
    Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
    Front Immunol; 2022; 13():898811. PubMed ID: 35967405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma.
    Wakabayashi K; Yamamoto S; Hara S; Okawara M; Teramoto K; Ikeda N; Kusunoki Y; Takeji M
    CEN Case Rep; 2022 May; 11(2):171-176. PubMed ID: 34524642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient.
    Chen M; Zhang L; Zhong W; Zheng K; Ye W; Wang M
    Front Immunol; 2021; 12():619147. PubMed ID: 34040602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature.
    Meyer N; Cooper W; Kirwan P; Garsia R; Dunkley S; Gracey DM
    BMC Nephrol; 2021 Jul; 22(1):268. PubMed ID: 34294065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombospondin type-1 domain-containing 7A-associated membranous nephropathy after resection of rectal cancer: a case report.
    Taguchi S; Koshikawa Y; Ohyama S; Miyachi H; Ozawa H; Asada H
    BMC Nephrol; 2019 Feb; 20(1):43. PubMed ID: 30727973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent membranous nephropathy with a possible alteration in the etiology: a case report.
    Matsumoto A; Matsui I; Mano K; Mizuno H; Katsuma Y; Yasuda S; Shimada K; Inoue K; Oki T; Hanai T; Kojima K; Kaneko T; Isaka Y
    BMC Nephrol; 2021 Jul; 22(1):253. PubMed ID: 34229600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
    Ishiwatari A; Wakai S; Shirakawa H; Honda K
    Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-glomerular basement membrane glomerulonephritis concurrent with membranous nephropathy and acute tubular interstitial nephritis in a lung cancer patient treated with pembrolizumab.
    Hoshina A; Endo S
    CEN Case Rep; 2023 May; 12(2):230-236. PubMed ID: 36401746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report.
    Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G
    Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain.
    L'Imperio V; Pieruzzi F; Sinico RA; Nebuloni M; Granata A; Smith A; Radice A; Pagni F
    J Nephrol; 2018 Aug; 31(4):543-550. PubMed ID: 29626294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of phospholipase A
    Yeter HH; Isik Gonul I; Eraslan E; Karacalik C; Ogut B; Guz G
    Clin Exp Nephrol; 2021 May; 25(5):488-500. PubMed ID: 33459908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma.
    Yasuda I; Tokuyama H; Hashiguchi A; Hasegawa K; Uchiyama K; Ryuzaki M; Yasuda M; Mizuno R; Ishidoya S; Wakino S; Itoh H
    CEN Case Rep; 2021 May; 10(2):281-286. PubMed ID: 33393071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
    Sise ME; Seethapathy H; Reynolds KL
    Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal expression of PLA2R, THSD7A, and IgG4 in patients with membranous nephropathy and correlation with clinical findings.
    Kaya B; Paydas S; Balal M; Eren Erdogan K; Gonlusen G
    Int J Clin Pract; 2021 Apr; 75(4):e13855. PubMed ID: 33249733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era.
    Safar-Boueri L; Piya A; Beck LH; Ayalon R
    Pediatr Nephrol; 2021 Jan; 36(1):19-30. PubMed ID: 31811540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
    Abe K; Ishikawa Y; Fujiwara M; Yukawa H; Yanagihara T; Takei S; Arioka H; Kita Y
    Medicine (Baltimore); 2022 Jan; 101(2):e28428. PubMed ID: 35029182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis.
    Yoshida K; Nagasaka N; Kondo T; Kobari Y; Ishihara H; Fukuda H; Iizuka J; Ishida H; Takagi T
    Int J Clin Oncol; 2024 Oct; 29(10):1538-1547. PubMed ID: 39110357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.